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the precision of radiotherapy delivery (e.g. computational algorithms,
IMRT, IGRT, SBRT); and3. Incorporationof novel radiosensitizing andmo-
lecular targeting agents with radiation therapy to reduce mechanisms of
radiation resistance (e.g. epithelial growth factor receptor inhibitors and
RT in head and neck cancer). Despite these achievements, determining
the beneﬁt of radiation therapy based on the molecular proﬁle of aPrecision medicine is rapidly evolving in themanagement of cancer,
critical for radiation oncologists to systematically evaluate tailored treat-
ment strategies for various malignancies based on the individual geneticin an effort to deliver the right therapy to the right patient at the right
time. The use of novel molecular or genetic signatures in decision mak-
ing regarding local–regional management is in its infancy.
In their recent work published in EBioMedicine, Cheng and col-
leagues developed an 18-gene classiﬁer capable of stratifying breast
cancer patients with 0–3 positive lymph nodes (N0–1) after mastecto-
my into low and high risk groups to better determine the need for
post-mastectomy radiation therapy (PMRT)(Cheng et al., 2016).
Through their work, they found that patients, who were deﬁned by
the 18-gene classiﬁer as high risk, had signiﬁcantly reduced rates of 5-
year loco-regional recurrence, distant metastasis-free survival, and
overall survival, regardless of lymph node status and breast cancer sub-
type based on estrogen receptor, progesterone receptor, and human
epidermal growth factor receptor 2/neu status.
The importance of this study lies in the fact that the gene expression
proﬁle developed by this group to support the decision for PMRT or not,
which is inmanyways similar to the OncotypeDx 21-gene panel, which
helps support the decision for adjuvant chemotherapy. This example of
gene expression proﬁling is exactly what is necessary to move the ﬁeld
of radiation oncology forward towards precision medicine (PM). PM
should not only integrate genomic data, but also relevant clinical, path-
ologic, and environmental parameters signiﬁcant to the patient
(Servant et al., 2014). The ability to improve outcomes in breast cancer
using radiation therapy should be focused on incorporating novel
genomic- or biology-based biomarkers, in addition to existing clinical
and pathologic features, in the treatment of patients.
Radiation therapy is a cornerstone ofmodernmultidisciplinary breast
cancer treatment. In the recent past, strategies to improve the outcome of
patients undergoing radiation therapy have centered on: 1. Advanced
imaging of tumor morphology and function for radiotherapy planningom.2016.02.022.
cology, Rutgers Cancer Institute
J 08903, USA.
. This is an open access article undertumor remains largely unresolved across the spectrum of cancers. It is
proﬁle of cancer (Collins and Varmus, 2015).
In reporting these results, the authors presented a shifting paradigm
in breast radiation oncology, namely using gene expression proﬁles to
identify patients likely to beneﬁt from PMRT in lieu of standard clinical
and pathologic features (Cheng et al., 2016). Weighing the potential
improvement in overall survival with PMRT against the potential
long-term toxicities associated with PMRT, namely potential cardiopul-
monary toxicity and secondarymalignancies, we are hopeful that in the
future, gene expression proﬁleswill help spare low-risk patients unlike-
ly to beneﬁt from PMRT and truly identify those patients at high risk of
recurrence that would beneﬁt from PMRT.
Prospective validation of this gene expression proﬁle in a larger
cohort of patients will be necessary to determine its prognostic and pre-
dictive impact in patients undergoingmastectomy. In addition, the cost-
effectiveness of gene expression proﬁles versus that of standardized
guidelines for patients who would beneﬁt from PMRT needs to be esti-
mated. Studies involving molecular proﬁling need to be developed to
help usher the ﬁeld of radiation oncology into the era of precisionmed-
icine in the 21st century.
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